Risperdal Lawsuit News: Pennsylvania Judge Bars Punitive Damages in Risperdal Litigation, Bernstein Liebhard LLP Reports

Share Article

The Firm is representing Risperdal lawsuit clients who allegedly developed gynecomastia (male breast growth) due to their use of the antipsychotic drug.

Free Case Review
Despite this ruling, plaintiffs in Risperdal lawsuits will still be able to pursue compensatory damages against Johnson & Johnson and Janssen.

The Pennsylvania judge overseeing hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) in the Philadelphia Court of Common Pleas has granted a defense motion to bar plaintiffs from seeking punitive damages. In an Order issued on May 2, 2014 Judge Arnold New ruled that the New Jersey Product Liability Act, which bars punitive damages in cases that involve medications approved by the U.S. Food & Drug Administration, would apply to the claims. Judge New agreed with the defense assertion that the New Jersey statute should govern the cases because Janssen Pharmaceuticals, the Johnson & Johnson unit that manufacturers Risperdal, is headquartered in the state. (Risperdal Litigation, case number 100300296)

“Our Firm is representing a number of clients in this litigation who allege Risperdal caused gynecomastia, or male breast growth. Despite this ruling, plaintiffs in Risperdal lawsuits will still be able to pursue compensatory damages against Johnson & Johnson and Janssen,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.

Risperdal Lawsuits
According to court documents, some 500 Risperdal lawsuits have been filed in the proceeding underway in Pennsylvania on behalf of patients who allegedly suffered gynecomastia and other side effects due to their use of the antipsychotic medication. Among other things, plaintiffs in these lawsuits accuse Johnson & Johnson and its Janssen Pharmaceuticals unit of concealing side effects associated with the medication, including the link between Risperdal and gynecomastia. Plaintiffs further allege that the companies improperly marketed Risperdal for off-label uses, including the treatment of children long before pediatric indications were approved in 2006.

On November 4, 2013, the U.S. Department of Justice announced that Johnson & Johnson and Janssen had agreed to settle charges that the companies had improperly marketed Risperdal and other medications. The $2.2 billion settlement was one of the largest involving healthcare fraud in U.S. history, according to the Justice Department. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Alleged victims of Risperdal and gynecomastia may be entitled to compensation from Johnson & Johnson and Janssen. Find out more about Risperdal lawsuits at Bernstein Liebhard LLP’s website. Free case reviews may also be obtained by calling the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website